TrialEuropean journal of haematology2015

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Henrik Hjorth-Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.